New trial finds liraglutide reduces brain shrinkage by nearly 50% in Alzheimer’s patients and slows cognitive decline by up to 18% ...

Some weight-loss and diabetes drugs can treat obesity when combined with exercise, a healthy diet, and counseling, according to WHO's first guidance on these medicines. The recommendations come amid ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed ...

Liraglutide significantly improves hepatic steatosis and metabolic parameters among patients with MASLD — without meaningful reductions in liver stiffness.

In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

(HealthDay News) — Liraglutide added to capped insulin is associated with reductions in glycated hemoglobin (HbA1c), body weight, and insulin requirements, according to a study published online Aug. 4 ...

The World Health Organization (WHO) on Monday issued its first-ever global guidelines on the use of GLP-1 medications for ...

Treatment with liraglutide (3.0 mg once daily for 3 years), a glucagon-like peptide 1 receptor agonist that lowers levels of glucose and reduces body weight, reduced the risk of 'on treatment' type 2 ...

In a phase 3 clinical trial, liraglutide was shown to reduce the body mass index in children ages 6 to 11 with obesity, according to a study published Sept. 10 in The New England Journal of Medicine.

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy and ...